Rein Therapeutics, Inc.
10-K
March 26, 2026
Key Highlights
- Strategic pivot to LTI-03 peptide platform for pulmonary fibrosis
- Successful $15 million capital raise to extend operations into Q2 2026
- Corporate rebranding from Aileron to Rein Therapeutics to signal new focus
Read Analysis
🤖 AI Generated